---
title: The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL
date: '2024-10-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39413830/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241017182600&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CAR T-cell therapy is a recent therapeutic advancement that has transformed
  the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia
  (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel
  in patients aged <26 years and brexucabtagene autoleucel in those aged ≥18 years.
  This review summarizes the pivotal clinical trials that led to FDA approval of these
  2 products and highlight emerging data addressing key questions pertinent to ...'
disable_comments: true
---
CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel in patients aged <26 years and brexucabtagene autoleucel in those aged ≥18 years. This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to ...